Antihypertensive class labeling
FDA's draft language for antihypertensive drug class labeling on cardiovascular outcomes claims will be considered by its Cardiovascular & Renal Drugs Advisory Committee on April 26. The committee proposed class labeling on improvement in cardiovascular outcomes from blood pressure reduction in June 2005 (1"The Pink Sheet" June 27, 2005, p. 8). The meeting, which will be held at the Hilton in Gaithersburg, Md. beginning at 8 a.m., will also address a meta-analysis of antihypertensive drug placebo-controlled trials. [Editor's note: To 2watch a webcastor order a video/DVD of this, or any other meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
Antihypertensive drug direct-to-consumer advertisements should include a statement that all drugs that lower blood pressure reduce risk of serious cardiovascular outcomes, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said April 27
Class labeling for reduction of cardiovascular outcomes based on blood pressure lowering should be applied to new classes of antihypertensives, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.